Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford team who have developed a COVID-19 vaccine in record time have been shortlisted for the Excellence in Healthcare Award at the NHS Parliamentary Awards.

Scientists analyzing covid 19 sample with microscope and holding covid 19 blood sample tube

The team from the Oxford Vaccine Group and Jenner Institute were nominated by Layla Moran, MP for Oxford West and Abingdon, and won the regional Excellence in Healthcare award.

The news coincided with announcement of interim data from phase III of the vaccine trial, which showed that the Oxford candidate vaccine was effective at preventing COVID-19 and offered a high level of protection. One dosing regimen indicated that the vaccine is 90 percent effective.

Layla Moran said:

"I'm absolutely delighted. There were nearly 700 nominations by MPs this year, so to be shortlisted is a huge achievement - the vaccine team really deserve it!

"The Oxford Vaccine Group and the Jenner Institute have been working so incredibly hard since the beginning of the pandemic to produce a vaccine that will be life changing for so many people around the world. They're the jewel in our community's crown"

The NHS Parliamentary Awards are an annual opportunity to recognise and appreciate the very best about our local healthcare service.

The full story is available on the Oxford University Hospitals website

Similar stories

From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford

Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed

It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard

A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees

Novel all-in-one vaccine developed to tackle future coronavirus threats

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

Professor Sir Andrew Pollard Awarded the James Spence Medal in 2022

Professor Sir Andrew Pollard, BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FIDSA FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Honorary Consultant Paediatrician at Oxford Children’s Hospital and Vice Master of St Cross College, Oxford.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.